Stable 2019 predicted for pharma despite political and regulatory risk, finds credit agency
Scope’s report finds biologics likely to be protected from severe biosimilar erosion but sees warning signs for the generics industry.
Top Headlines
Global Industry News
-
Insulin biosimilars? US FDA readies market for entry
from BioPharma-Reporter.com
-
Chinese firm plans ‘first-in-class’ biologics after $325m manufacturing investment
from BioPharma-Reporter.com
-
Biorasi closes PE deal, next stage to be ‘vastly different’ as CRO plans scale-up
from Outsourcing-Pharma.com
-
Smithers Avanza: New lab to support all phases of biotherapeutics development
from Outsourcing-Pharma.com
Hot Topics
-
Is big pharma invested in small molecules? An ethical question
Globalisation
-
Akorn CEO resigns after Fresenius merger collapses
Mergers and Acquisitions
-
Simpler drug delivery through capsule-based inhalation
Bioavailability Challenge
-
Takeda’s $62bn Shire acquisition is a go following shareholder votes
Mergers and Acquisitions
